Mayo Clinic proceedings最新文献

{"title":"Total Laryngeal Transplant in the Setting of Active Laryngeal Malignancy","authors":"David G. Lott MD ,&nbsp;Girish K. Mour MBBS ,&nbsp;Danielle N. Grandjean PhD ,&nbsp;Stephanie R.C. Zacharias PhD, CCC-SLP ,&nbsp;Elizabeth H. Stearns PA-C, MS, MBA ,&nbsp;Brent A. Chang MD ,&nbsp;Payam Entezami MD, MS ,&nbsp;Michael L. Hinni MD ,&nbsp;Brittany E. Howard MD ,&nbsp;Melissa Zheng MD","doi":"10.1016/j.mayocp.2024.07.001","DOIUrl":"10.1016/j.mayocp.2024.07.001","url":null,"abstract":"<div><p>Laryngeal transplant (LT) is a promising option to restore quality of life in patients with severe laryngeal dysfunction or a laryngectomy. These patients may be tracheostomy tube dependent or gastrostomy tube dependent and may lose their ability to verbally communicate. The loss of these important functions frequently results in social isolation and a severe decrease in quality of life. Laryngeal transplant has the potential to restore all of these important laryngeal functions. Herein, we report the first known documented LT performed in the setting of laryngeal chondrosarcoma.</p></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1445-1448"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CIC-Rearranged Round Cell Sarcoma","authors":"Jorge Torres-Mora MD,&nbsp;Lori A. Erickson MD","doi":"10.1016/j.mayocp.2024.07.012","DOIUrl":"10.1016/j.mayocp.2024.07.012","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1528-1529"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0025619624003562/pdfft?md5=5e1fb5b345ca22ab244e4e55433691f5&pid=1-s2.0-S0025619624003562-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developments and Controversies in Invasive Diagnosis of Coronary Microvascular Dysfunction in Angina With Nonobstructive Coronary Arteries","authors":"Kara J. Denby MD ,&nbsp;Mohammad Zmaili MD ,&nbsp;Sudarshana Datta MD ,&nbsp;Thomas Das MD ,&nbsp;Stephen Ellis MD ,&nbsp;Khaled Ziada MD ,&nbsp;Amir Lerman MD ,&nbsp;Claire E. Raphael MBBS, PhD","doi":"10.1016/j.mayocp.2024.04.022","DOIUrl":"10.1016/j.mayocp.2024.04.022","url":null,"abstract":"<div><p>Approximately half of all coronary angiograms performed for angina do not show obstructive coronary artery disease, and many of these patients have coronary microvascular dysfunction (CMD). Invasive testing for CMD has increased with the advent and wider availability of thermodilution systems. We review CMD pathophysiology and invasive diagnostic testing using the Doppler and thermodilution systems. We report the results of a PubMed search of invasive microvascular testing and discuss limitations of current diagnostic algorithms in the diagnosis of CMD, including controversies regarding the optimal cutoff value for abnormal coronary flow reserve, use of microvascular resistance indices, and options for increasing sensitivity of testing.</p></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1469-1481"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S002561962400212X/pdfft?md5=6becfa7cb403ba397de5486833ced78b&pid=1-s2.0-S002561962400212X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of Recent Literature and Updates in Nonstatin Cholesterol Management","authors":"","doi":"10.1016/j.mayocp.2024.03.001","DOIUrl":"10.1016/j.mayocp.2024.03.001","url":null,"abstract":"<div><p>The guidelines for cholesterol management have been updated over the years from treat-to-target using any drug class to emphasis on statins without treatment targets to a hybrid of the 2 approaches. The most recent guideline updates include newer nonstatin lipid-lowering therapies (LLTs), low-density lipoprotein cholesterol (LDL-C) reduction goals, and LDL-C thresholds considering secondary prevention and cardiovascular risk. Although statins have been the mainstay of LLT for years, newer pharmacological agents such as proprotein convertase subtilisin-kexin type 9 inhibitor(s) (PCSK9i) monoclonal antibodies, small interfering RNA PCSK9i, and bempedoic acid to optimize LDL-C levels may be underutilized in clinical practice. To provide an updated review for clinicians, we performed a literature search in PubMed for articles published from January 1, 2000, to August 31, 2023, that included the terms <em>cholesterol</em>, <em>LLT</em>, <em>bempedoic acid</em>, <em>inclisiran</em>, or <em>PCSK9 inhibitor</em>. Studies were selected for inclusion according to relatedness to cholesterol management and outcomes with novel LLT agents. Optimization of statins can improve the lipid profile and contribute to primary and secondary atherosclerotic cardiovascular disease (ASCVD) prevention. The newest guidance combines anticipated LDL-C reduction from statins and LDL-C thresholds for primary and secondary prevention. Nonstatin agents such as PCSK9i monoclonal antibodies, small interfering RNA PCSK9i, and bempedoic acid are safe and effective LLTs that can be used in addition to statin therapy for additional LDL-C lowering and prevention of ASCVD. Additionally, these nonstatin agents are reasonable to initiate in patients who have not been able to tolerate statins due to myalgias, rhabdomyolysis, or contraindications. Cost may be a barrier to initiating these agents for patients who are underinsured or uninsured. Clinicians should reference the most up-to-date guidance for LLT for primary and secondary prevention of ASCVD. Additionally, clinicians must diligently continue to optimize statin and nonstatin LLT to improve cardiovascular health outcomes.</p></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1449-1468"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0025619624001332/pdfft?md5=f0ef44c4d379b7cb74958eb2de1e80e8&pid=1-s2.0-S0025619624001332-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Primary Care Physician Burnout From Electronic Health Record Use Measures","authors":"","doi":"10.1016/j.mayocp.2024.01.005","DOIUrl":"10.1016/j.mayocp.2024.01.005","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the ability of routinely collected electronic health record (EHR) use measures to predict clinical work units at increased risk of burnout and potentially most in need of targeted interventions.</p></div><div><h3>Methods</h3><p>In this observational study of primary care physicians, we compiled clinical workload and EHR efficiency measures, then linked these measures to 2 years of well-being surveys (using the Stanford Professional Fulfillment Index) conducted from April 1, 2019, through October 16, 2020. Physicians were grouped into training and confirmation data sets to develop predictive models for burnout. We used gradient boosting classifier and other prediction modeling algorithms to quantify the predictive performance by the area under the receiver operating characteristics curve (AUC).</p></div><div><h3>Results</h3><p>Of 278 invited physicians from across 60 clinics, 233 (84%) completed 396 surveys. Physicians were 67% women with a median age category of 45 to 49 years. Aggregate burnout score was in the high range (≥3.325/10) on 111 of 396 (28%) surveys. Gradient boosting classifier of EHR use measures to predict burnout achieved an AUC of 0.59 (95% CI, 0.48 to 0.77) and an area under the precision-recall curve of 0.29 (95% CI, 0.20 to 0.66). Other models’ confirmation set AUCs ranged from 0.56 (random forest) to 0.66 (penalized linear regression followed by dichotomization). Among the most predictive features were physician age, team member contributions to notes, and orders placed with user-defined preferences. Clinic-level aggregate measures identified the top quartile of clinics with 56% sensitivity and 85% specificity.</p></div><div><h3>Conclusion</h3><p>In a sample of primary care physicians, routinely collected EHR use measures demonstrated limited ability to predict individual burnout and moderate ability to identify high-risk clinics.</p></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1411-1421"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0025619624000375/pdfft?md5=cf6dc8118af2c5a24e0ccf7daee24227&pid=1-s2.0-S0025619624000375-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Colchicine on Major Adverse Limb and Cardiovascular Events in Patients With Peripheral Artery Disease","authors":"Donna Shu-Han Lin MD ,&nbsp;Kuan-Chih Huang PhD ,&nbsp;Ting-Tse Lin PhD ,&nbsp;Jen-Kuang Lee PhD ,&nbsp;Lian-Yu Lin PhD","doi":"10.1016/j.mayocp.2024.05.004","DOIUrl":"10.1016/j.mayocp.2024.05.004","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the effects of colchicine, which has been shown to reduce the risks of coronary artery disease but scarcely studied in peripheral artery disease (PAD), on major adverse limb events (MALE) in patients with PAD.</p></div><div><h3>Methods</h3><p>This is a retrospective study based on a nationwide database. Patients who were diagnosed with PAD between 2010 and 2020 and prescribed with colchicine after the diagnosis of PAD were identified. Patients were then categorized into the colchicine or the control group according to drug use. Propensity score matching was performed to mitigate selection bias. Risks of MALE (including lower limb revascularization and nontraumatic amputation) and major adverse cardiovascular events were compared between the two groups.</p></div><div><h3>Results</h3><p>After patient selection and propensity score matching, there were 60,219 patients in both colchicine and control groups. After a mean follow-up of 4.5 years, the risk of MALE was significantly lower in the colchicine group compared with control (subdistribution HR, 0.75; 95% CI, 0.71 to 0.80), as were the incidence of both components of MALE, lower limb revascularization and major amputations. Colchicine treatment was also associated with lower risk of cardiovascular death. The lower risk of MALE observed with colchicine therapy was accentuated in the subgroup of patients receiving concomitant urate-lowering medications.</p></div><div><h3>Conclusion</h3><p>In patients diagnosed with PAD, the use of colchicine is associated with lower risks of MALE and cardiovascular death. Anti-inflammatory therapy with colchicine may provide benefits in vascular beds beyond the coronary arteries.</p></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1374-1387"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Risk and Coronary Artery Calcium in Personalizing Antihypertensive Treatment: A Pooled Cohort Analysis","authors":"Naman S. Shetty MD ,&nbsp;Mokshad Gaonkar MS ,&nbsp;Akhil Pampana MS ,&nbsp;Nirav Patel MD ,&nbsp;Marguerite R. Irvin PhD ,&nbsp;Henry J. Lin MD ,&nbsp;Xiuqing Guo PhD ,&nbsp;Stephen S. Rich PhD ,&nbsp;Jerome I. Rotter MD ,&nbsp;Matthew J. Budoff MD ,&nbsp;Peng Li PhD ,&nbsp;Garima Arora MD ,&nbsp;Pankaj Arora MD","doi":"10.1016/j.mayocp.2023.12.020","DOIUrl":"10.1016/j.mayocp.2023.12.020","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the role of the systolic blood pressure polygenic risk score (SBP-PRS) in antihypertensive treatment initiation and its comparative efficacy with coronary artery calcium (CAC) scores.</p></div><div><h3>Patients and Methods</h3><p>This retrospective cohort study included participants with whole genome sequencing data who underwent CAC scanning between 1971 and 2008, were free of prevalent cardiovascular disease (CVD), and were not taking antihypertensive medications. The cohort was stratified by blood pressure (BP) treatment group and SBP-PRS (low/intermediate, first and second tertiles; high, third tertile) and CAC score (0 vs &gt;0) subgroups. The primary outcome was the first occurence of adjudicated coronary heart disease, heart failure, or stroke during 10-year follow-up. The 10-year number needed to treat (NNT) to prevent 1 event of the primary outcome was estimated. A relative risk reduction of 25% for the primary outcome based on the treatment effect of intensive control (SBP &lt;120 mm Hg) of hypertension in SPRINT (Systolic Blood Pressure Intervention Trial) was used for estimating the NNT.</p></div><div><h3>Results</h3><p>Among the 5267 study participants, the median age was 59 years (interquartile range, 51-68 years); 2817 (53.5%) were women and 2880 (54.7%) were non-White individuals. Among 1317 individuals with elevated BP/low-risk stage 1 hypertension not recommended treatment, the 10-year incidence rate of the primary outcome was 5.6% for low/intermediate SBP-PRS and 6.3% for high SBP-PRS with NNTs of 63 and 59, respectively. Similarly, the 10-year incidence rate of the primary outcome was 2.9% for CAC score 0 and 9.7% for CAC score greater than 0, with NNTs of 117 and 37, respectively.</p></div><div><h3>Conclusion</h3><p>Including genetic information in risk estimation of individuals with elevated BP/low-risk stage 1 hypertension has modest value in the initiation of antihypertensive therapy. Genetic risk and CAC both have efficacy in personalizing antihypertensive therapy.</p></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1422-1434"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Six Centuries of Raeapteek in Estonia: The Oldest Surviving Pharmacy Still Open to the Public","authors":"David P. Steensma MD","doi":"10.1016/j.mayocp.2024.07.002","DOIUrl":"10.1016/j.mayocp.2024.07.002","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1530-1531"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0025619624003239/pdfft?md5=0ce664f876df8118bb15edb97fde3ffe&pid=1-s2.0-S0025619624003239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In the Limelight: September 2024","authors":"Karl A. Nath MBChB (Editor-in-Chief)","doi":"10.1016/j.mayocp.2024.07.026","DOIUrl":"10.1016/j.mayocp.2024.07.026","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1351-1353"},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0025619624003756/pdfft?md5=0eb203b7237c0c77a87a4a85f85d7741&pid=1-s2.0-S0025619624003756-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In the Limelight: August 2024","authors":"Karl A. Nath MBChB (Editor-in-Chief)","doi":"10.1016/j.mayocp.2024.06.012","DOIUrl":"10.1016/j.mayocp.2024.06.012","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 8","pages":"Pages 1199-1201"},"PeriodicalIF":6.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141889736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}